Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
Holly Jane Meany
No relevant relationships to disclose
Jeffrey Dome
No relevant relationships to disclose
Pamela S. Hinds
No relevant relationships to disclose
Rochelle Bagatell
No relevant relationships to disclose
Suzanne Shusterman
No relevant relationships to disclose
Brigitte C. Widemann
No relevant relationships to disclose
Emily Stern
No relevant relationships to disclose
Wendy B. London
No relevant relationships to disclose
AeRang Kim
No relevant relationships to disclose
Elizabeth Fox
No relevant relationships to disclose
Carlos Rodriguez-Galindo
No relevant relationships to disclose
Jane E. Minturn
No relevant relationships to disclose